Literature DB >> 4192093

Amantadine dosage in treatment of Parkinson's disease.

J D Parkes, K J Zilkha, P Marsden, R C Baxter, R P Knill-Jones.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4192093     DOI: 10.1016/s0140-6736(70)91211-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  25 in total

1.  Parkinsonism-physiology and pharmacology.

Authors:  D B Calne
Journal:  Br Med J       Date:  1971-09-18

Review 2.  Augmenting the action of levodopa.

Authors:  S K Rao; S D Vakil; D B Calne; A Hilson
Journal:  Postgrad Med J       Date:  1972-11       Impact factor: 2.401

3.  The comparative value of amantadine and levodopa.

Authors:  V Dallos; K Heathfield; P Stone; F Allen
Journal:  Postgrad Med J       Date:  1972-06       Impact factor: 2.401

4.  An extended clinical trial to compare levodopa and amantadine used as single drugs with both drugs used incombination in Parkinson's Disease.

Authors:  N Calaghan; M McIlroy; M O'Connor
Journal:  Ir J Med Sci       Date:  1974-03       Impact factor: 1.568

5.  Treatment of Parkinson's Disease with levodopa and amantadine used as single drugs and in combined therapy.

Authors:  N Callagham; M Mcllroy; M O'Connor
Journal:  Ir J Med Sci       Date:  1974-03       Impact factor: 1.568

6.  Proceedings: Effect of amantadine on the urinary excretion of some monoamines and metabolites in normal and parkinsonian subjects.

Authors:  D G Jones; J A Lenman; M A Robertson; M J Turnbull
Journal:  Br J Pharmacol       Date:  1972-02       Impact factor: 8.739

7.  Treatment for Parkinsonism, other than levodopa.

Authors: 
Journal:  Br Med J       Date:  1972-03-18

Review 8.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 9.  Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.

Authors:  B K Young; R Camicioli; L Ganzini
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

10.  Amantadine-HCl (Symmetrel) in the management of Parkinson's disease: a double-blind cross-over study.

Authors:  A Barbeau; H Mars; M I Botez; M Joubert
Journal:  Can Med Assoc J       Date:  1971-07-10       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.